Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28702490 | 1.00 | TSHR (0.37) | TSHRMAPK1HSD17B10TDP1THRB | |
| Iodide SCHEMBL10567947 | 0.98 | TSHR (0.36) | TSHRMAPK1HSD17B10TDP1THRB | |
| Water SCHEMBL28685341 | 0.98 | TSHR (0.36) | TSHRMAPK1HSD17B10TDP1THRB | |
| SCHEMBL27766138 | 0.84 | TSHR (0.32) | TSHRMAPK1HSD17B10TDP1THRB | |
| SCHEMBL1268596 | 0.83 | — | — | |
| Acetic Acid SCHEMBL2788321 | 0.81 | TSHR (0.33) | TSHRMAPK1HSD17B10TDP1THRB | |
| SCHEMBL30514305 | 0.81 | — | — | |
| Iodide SCHEMBL3065810 | 0.80 | GABRR1 (0.33) | TSHRMAPK1HSD17B10TDP1THRB | |
| Hydrochloric Acid SCHEMBL134284 | 0.80 | THRB (0.34) | TSHRMAPK1HSD17B10TDP1THRB | |
| SCHEMBL3449675 | 0.79 | BAZ2B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295624-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2025-09-25 | — | — | US | claimed |
| CN-120195298-A | Metabolic marker composition for discriminating tobacco grades, screening method and application | 哈尔滨脉图精准技术有限公司 | 2025-06-24 | — | — | CN | claimed |
| EP-3321686-B1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | METABOLON INC (US) | 2024-03-13 | — | — | EP | claimed |
| EP-3554258-B1 | COMPOSITIONS AND METHODS THAT MODULATE PHOSPHORUS OR ENZYMES IN A COMPANION ANIMAL | NESTLE SA (CH) | 2023-07-19 | — | — | EP | claimed |
| EP-3554263-B1 | COMPOSITIONS AND METHODS THAT MODULATE DIGESTIBILITY IN A COMPANION ANIMAL | NESTLE SA (CH) | 2023-07-19 | — | — | EP | claimed |
| US-20220003753-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ADS PHENOTYPE 1 | STALICLA SA (CH) | 2022-01-06 | — | — | US | claimed |
| CN-113490489-A | Monomethyl fumarate-carrier conjugates and methods of use thereof | 旗舰创业创新五公司 | 2021-10-08 | — | — | CN | claimed |
| CN-113166811-A | Metabolic profiling for diagnosing subtype ASD phenotype 1 in patients with idiopathic autism spectrum disorders | 斯大利卡拉公司 | 2021-07-23 | — | — | CN | claimed |
| CN-109642337-B | Ternary zinc-nickel-iron alloy and alkaline electrolyte for electroplating such an alloy | 科文特亚股份有限公司 | 2021-07-13 | — | — | CN | claimed |
| US-11040117-B2 | Treatment of a subtype of ASD | Stalicla S.A. (CH) | 2021-06-22 | — | — | US | claimed |
| EP-1888115-A2 | COMPOUNDS FOR PHOTOCHEMOTHERAPY | UNIVERSITE DE GENEVE (CH) | 2008-02-20 | — | — | EP | claimed |
| US-20070259861-A1 | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries | PHARMENA NORTH AMERICA INC. (CA) | 2007-11-08 | — | — | US | claimed |
| WO-2007103540-A2 | COMBINATION THERAPY WITH NON-SELECTIVE COX INHIBITORS TO PREVENT COX-RELATED GASTRIC INJURIES | PHARMENA NORTH AMERICA INC. (CA) | 2007-09-13 | — | — | WO | claimed |
| WO-2007074406-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2007-07-05 | — | — | WO | claimed |
| WO-2007023398-A2 | COMPOUNDS FOR PHOTOCHEMOTHERAPY | UNIVERSITE DE GENEVE (US) | 2007-03-01 | — | — | WO | claimed |
| EP-1147086-B1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2005-03-30 | — | — | EP | claimed |
| US-6403658-B1 | Genital vasodilator | TOPPO, FRANK | 2002-06-11 | — | — | US | claimed |
| EP-1147086-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | Technical University of Lodz (PL) | 2001-10-24 | — | — | EP | claimed |
| WO-2000040559-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2000-07-13 | — | — | WO | claimed |
| US-4332792-A | Insect attractant | ZOECON CORPORATION (US) | 1982-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259861-A1 | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries | PTGS1, PTGS2, PTGES2 | TSHR 3705/4885MAPK1 1725/4885HSD17B10 2592/4885 |
| US-20250295624-A1 | MONOMETHYL FUMARATE-CARRIER CONJUGATES AND METHODS OF THEIR USE | SLC16A1, SLC16A3, SLC16A8 | TSHR 4607/4885MAPK1 4249/4885HSD17B10 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.